Valeant Pharmaceuticals International Inc. is counting on teenagers' back-to-school skin concerns to help boost the company's profits in the second half of this year and save its dermatology business, which had a 55% decline in revenues in the second quarter from the same period a year ago.
Valeant's Dermatology Sales Strategy: Teenage Zits
Valeant Pharmaceutical International Inc.'s dermatology business is in trouble. But CEO Joseph Papa said the company is counting on teenagers eager to have clear skin when they return to school in the fall to boost prescriptions of the firm's acne medicine Solodyn (minocycline).
More from Dermatological
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.